Our mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases.

Taking Big Steps

Visit our Online Magazine

MorphoSys' mission

MorphoSys mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

05/08/2020
MorphoSys Reports Second Quarter and First Half 2020 Results
01/08/2020
FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with...
01/08/2020
MorphoSys AG: Ad hoc: FDA Approves Monjuvi(R) (tafasitamab-cxix) in...
30/07/2020
Invitation to MorphoSys' Second Quarter and First Half 2020 Results...
14/07/2020
MorphoSys' Licensee Janssen Announces Approval of Tremfya (Guselkumab...
02/06/2020
MorphoSys to Present at Upcoming Virtual Investor Conferences
27/05/2020
MorphoSys AG Reports Outcome of Annual General Meeting 2020
20/05/2020
MorphoSys and Incyte Announce the Validation of the European Marketing...
14/05/2020
MorphoSys to Present Data on Tafasitamab at the ASCO and EHA Virtual...
14/05/2020
MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND...

August 6, 2020
Webcast & Conference Call
Q2/H1 2020 Financial Results

Full details